Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 6/20 | 0.42 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1625003 | 0.88 | F10 (0.46) | F2PLAUKMT2AMEN1F10 | |
| SCHEMBL1622154 | 0.87 | ALDH1A1 (0.46) | ALDH1A1HPGDTP53F2PLAU | |
| SCHEMBL1622988 | 0.85 | F2 (0.55) | ALDH1A1HPGDF2KMT2AMEN1 | |
| SCHEMBL1624612 | 0.84 | NR1H4 (0.49) | ALDH1A1HPGDTP53F2PLAU | |
| SCHEMBL1624128 | 0.83 | F2 (0.49) | F2PLAUF10PRSS1HDAC1 | |
| SCHEMBL1623574 | 0.83 | F2 (0.53) | F2F10PRSS1HDAC1HDAC6 | |
| SCHEMBL1624480 | 0.82 | GAA (0.45) | HPGDF2PLAUKMT2AF10 | |
| SCHEMBL1624473 | 0.81 | PKM (0.49) | ALDH1A1F2KMT2AMEN1F10 | |
| SCHEMBL1622251 | 0.81 | F10 (0.47) | F2F10PRSS1HDAC1HDAC6 | |
| SCHEMBL1624584 | 0.81 | HDAC1 (0.47) | F2KMT2AMEN1F10PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7928137-B2 | Meta-benzamidine derivatives as serine protease inhibitors | TULARIK LIMITED (GB) | 2011-04-19 | — | — | US | disclosed |
| US-20070155790-A1 | Meta-benzamidine derivatives as serine protease inhibitors | LIEBESCHUETZ JOHN W | 2007-07-05 | — | — | US | disclosed |
| US-7220781-B2 | Meta-benzamidine derivatives as serine protease inhibitors | TULARIK LIMITED (GB) | 2007-05-22 | — | — | US | disclosed |
| EP-1009758-B1 | META-BENZAMIDINE DERIVATIVES AS SERINE PROTEASE INHIBITORS | TULARIK LTD (GB) | 2005-06-01 | — | — | EP | disclosed |
| US-20040143018-A1 | Meta-benzamidine derivatives as serine protease inhibitors | LIEBESCHUETZ JOHN WALTER (GB) | 2004-07-22 | — | — | US | disclosed |
| US-6740682-B2 | TREATMENT OF THROMBOTIC DISEASES, ASTHMA, EMPHYSEMA, CIRRHOSIS, ARTHRITIS, CARCINOMA, MELANOMA, RESTENOIS, ATHEROMA, TRAUMA, SHOCK AND REPERFUSION INJURY. | TULARIK LIMITED (GB) | 2004-05-25 | — | — | US | disclosed |
| US-20020055522-A1 | Meta-benzamidine derivatives as serine protease inhibitors | TULARIK LIMITED (GB) | 2002-05-09 | — | — | US | disclosed |
| EP-1009758-A1 | META-BENZAMIDINE DERIVATIVES AS SERINE PROTEASE INHIBITORS | Protherics Molecular Design Limited (GB) | 2000-06-21 | — | — | EP | disclosed |
| WO-1999011658-A1 | META-BENZAMIDINE DERIVATIVES AS SERIN PROTEASE INHIBITORS | PROTEUS MOLECULAR DESIGN LTD. (GB) | 1999-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020055522-A1 | Meta-benzamidine derivatives as serine protease inhibitors | SERPINE1, PEPD, PRSS1 | ALDH1A1 3629/4885HPGD 1469/4885TP53 3169/4885 |
| US-20070155790-A1 | Meta-benzamidine derivatives as serine protease inhibitors | PEPD, SERPINE1, HPN | ALDH1A1 4419/4885HPGD 1199/4885TP53 2563/4885 |
| US-20040143018-A1 | Meta-benzamidine derivatives as serine protease inhibitors | SERPINE1, PEPD, PRSS1 | ALDH1A1 3629/4885HPGD 1469/4885TP53 3169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.